SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
Balance Sheet
Inspect the capital base behind the business.
Assets
$115.87M
FY 2025 · Annual
Liabilities
$214.70M
FY 2025 · Annual
Equity
-$98.84M
FY 2025 · Annual
Balance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $238.9M |
| Short-term Investments | $12.1M |
| Receivables | $653.0K |
| Other Current | $1.7M |
| Total Current Assets | $253.4M |
| PP&E (Net) | $4.2M |
| Other Non-current | $789.0K |
| Total Non-current Assets | $5.0M |
| Total Assets | $258.4M |
Analysis
Selected assets total $258.4M for Latest. The largest visible component is Cash & Equivalents at $238.9M, about 92.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Oct 19, 2026 | |
| 8-K | Current report | Oct 1, 2026 | |
| 10-Q | Quarterly report | Aug 6, 2026 |
How much cash does SGP have?
SpyGlass Pharma, Inc. Common Stock (SGP) reported $96.36M in cash and equivalents in fiscal 2025.
How much debt does SGP carry?
SpyGlass Pharma, Inc. Common Stock (SGP) reported $1.58M of total debt, with net debt of -$94.78M.
Continue the stock analysis
Jump to another research area for this company.